Use of cancer chemotherapy agents or rituximab to treat autoimmune diseases was associated with an increased risk of pulmonary fibrosis (PF) in people hospitalized with COVID-19, according to a large-scale U.S. study. Exposure to these medications, along with anti-inflammatory corticosteroids and amiodarone, used to treat certain heart rhythm disorders,…
News
LYT-100, PureTech Health’s oral treatment candidate for idiopathic pulmonary fibrosis (IPF), was well tolerated among healthy older adults at doses leading to much higher amounts of active medication in the body than the approved dose of Esbriet (pirfenidone). That’s according to new data from Phase 1 clinical…
Proteins called histones can trigger lung fibrosis (scarring) by prompting platelets, cell fragments involved in blood clotting, to release a signaling molecule called transforming growth factor beta 1 (TGFB1), a new study found. TGFB1, in turn, blocks the production of interleukin-27 (IL-27), a signaling molecule that normally helps to limit…
Treatment with AP01, Avalyn Pharma‘s experimental inhaled formulation of pirfenidone, appears to be slightly more effective for idiopathic pulmonary fibrosis (IPF) than the oral version, which is sold as Esbriet, and results in fewer side effects. AP01’s efficacy and safety profiles with progressive forms of pulmonary…
The experimental oral therapy BMS-986278, taken at 60 mg twice daily for 26 weeks, resulted in a 69% reduction in the rate of lung function decline in adults with progressive pulmonary fibrosis taking part in a Phase 2 trial. These findings are consistent with previously reported data from…
A Phase 2a clinical trial to evaluate the safety and efficacy of ENV-101 (taladegib), Endeavor BioMedicines’ oral treatment for idiopathic pulmonary fibrosis (IPF), has completed patient enrollment. Top-line data from the study (NCT04968574), which enrolled 41 adults with mild-to-moderate IPF, ages 40 and older, at sites in…
The first patients have been dosed in the Phase 2 REVERTIPF trial testing Tvardi Therapeutics’ investigational therapy TTI-101 in people with idiopathic pulmonary fibrosis (IPF). TTI-101 is an oral small molecule inhibitor of STAT3, a protein implicated in pulmonary fibrosis (PF), as well as certain types of cancer. The…
Scientists have developed a way to use engineered specialized stem cells to regenerate healthy airway tissues, offering a potential avenue for treating chronic lung diseases like pulmonary fibrosis (PF). In a pair of proof-of-concept preclinical studies published in Cell Stem Cell, scientists described how they engineered lung stem…
Supporters are gearing up to mark Pulmonary Fibrosis Awareness Month, set aside every September, to call attention to the rare lung disease that affects more than 250,000 individuals in the U.S. and 400,000 in Europe. For its part, the Pulmonary Fibrosis Foundation (PFF), with its campaign theme “Embrace Your…
The U.S. Food and Drug Administration (FDA) has approved a new generic version of Esbriet (pirfenidone) for idiopathic pulmonary fibrosis (IPF), according to an announcement by Lupin, the global pharmaceutical company that will market the medication. As with the brand name medicine, Lupin‘s generic will be available…
